by Harriet Boyd | Jul 2024 | Blogs
Advantages of using VHH antibodies for CAR engineering Since the first anti-CD19 CAR-T cell therapy was approved in 2017, there’s been an explosion of interest in using engineered immune cells to treat cancer. CAR constructs consist of an external antibody-based...
by Harriet Boyd | Jul 2024 | Blogs
Small antibodies, big libraries Why size matters when it comes to synthetic VHH discovery If you work in the antibody discovery space, you’ve probably considered using synthetic libraries at some point. You might have heard about the speed at which they can generate...
by Harriet Boyd | Jun 2024 | Blogs
Appetite for destruction: ‘Plug and play’ targeted protein degradation using synthetic VHH antibodies to take out tricky targets A recent study demonstrating the effectiveness of single domain antibody-directed protein degradation adds to this new and expanding...
by Harriet Boyd | Jun 2024 | Blogs
‘Intrabodies’ – Isogenica’s VHH antibodies improve heart function when delivered intracellularly Our VHH antibodies have been put to the test as a potential new therapy for heart failure in an early-stage study from AstraZeneca published in...
by Harriet Boyd | May 2024 | Blogs
2-for-1 VHH antibody engineering Humanising and improving antibody affinity all in one step Sometimes the smallest of molecules pose the greatest challenges. This was the case when a partner approached us with what turned out to be a VHH antibody engineering...
by Harriet Boyd | May 2024 | Bi-specific resources, Blogs, VHHs
VHH Humanisation Unlike conventional IgG antibodies from humans or mice, VHHs (also known as nanobodies) are composed solely of the single variable domain of a heavy chain. Originally derived from llamas, VHH antibody humanisation is often required. Here we compare...